Abstract
Trastuzumab resistance is a common problem that impedes the effectiveness of trastuzumab in ErbB2-amplified cancers. About 70% of ErbB2-amplified breast cancers do not respond to trastuzumab (de novo resistance), and the majority of the trastuzumab-responsive cancers progress within 1 year (acquired resistance). Different mechanisms exist between de novo and acquired resistance. Innate resistance mechanisms are mainly independent of ErbB2 receptor activity, and acquired resistance involves with alterations depending on ErbB2 activity. We previously reported H2-18, an ErbB2 domain I-specific antibody, which could circumvent de novo resistance to trastuzumab. Here, we modeled the development of acquired resistance by treating human gastric cancer cell line NCI-N87 with trastuzumab to obtain the trastuzumab-resistant subline, NCI-N87-TraRT. Next, we investigated the antitumor efficacy of H2-18 in NCI-N87-TraRT cell line. H2-18 exhibited a significantly greater antitumor activity in NCI-N87-TraRT tumor-bearing nude mice than pertuzumab and trastuzumab, either alone or in combination. The unique ability of H2-18 to overcome acquired resistance may be attributable to its potent programmed cell death-inducing activity, which was proba...Continue Reading
References
May 12, 1989·Science·D J SlamonA Ullrich
Jan 9, 1987·Science·D J SlamonW L McGuire
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles L VogelMichael Press
Sep 10, 2005·Cancer Immunology, Immunotherapy : CII·Camellia W AdamsMark X Sliwkowski
May 10, 2006·Nature Clinical Practice. Oncology·Rita NahtaFrancisco J Esteva
Aug 22, 2006·Current Opinion in Cell Biology·Satyajit K Mitra, David D Schlaepfer
Nov 14, 2006·Breast Cancer Research : BCR·Rita Nahta, Francisco J Esteva
Feb 24, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lyndsay N HarrisEric P Winer
May 26, 2007·Oncogene·C GinestierD Birnbaum
Oct 2, 2007·Biochimica Et Biophysica Acta·Evan Ingley
Oct 16, 2007·Cancer Cell·Katrien BernsRené Bernards
Apr 3, 2008·Cancer Research·Bohua LiYajun Guo
Apr 7, 2009·The Oncologist·Jeffrey S RossGabriel N Hortobagyi
Dec 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David JackmanVincent A Miller
Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José BaselgaLuca Gianni
Mar 15, 2011·Nature Medicine·Siyuan ZhangDihua Yu
Mar 7, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Javier CortésJosé Baselga
Apr 5, 2012·Critical Reviews in Oncogenesis·Brent N Rexer, Carlos L Arteaga
Jan 31, 2015·Oncotarget·Shi HuYajun Guo
Feb 24, 2015·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Alexandra Thiel, Ari Ristimäki
Sep 15, 2015·Critical Reviews in Oncology/hematology·Ksenija Asić
Aug 27, 2016·Oncotarget·Qiong LuBohua Li
Citations
Sep 29, 2018·Future Oncology·Zhe WangYefu Liu
Aug 15, 2020·Frontiers in Oncology·Sudath Hapuarachchige, Dmitri Artemov
Jul 25, 2021·Cancers·Hamid MaadiZhixiang Wang
Jul 15, 2021·Proceedings of the National Academy of Sciences of the United States of America·Rosalynd UptonIrving L Weissman